PMC:7405836 / 115443-116209 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T38","span":{"begin":551,"end":556},"obj":"Body_part"},{"id":"T39","span":{"begin":660,"end":666},"obj":"Body_part"}],"attributes":[{"id":"A38","pred":"fma_id","subj":"T38","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A39","pred":"fma_id","subj":"T39","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"Further assessment is necessary before confirming the effectiveness of such combination therapy. In addition, to prevent further community and nosocomial spread of COVID-19, the postprocedure risk management program should not be neglected (309). Development of broad-spectrum inhibitors against the human coronaviral pathogens will help to facilitate clinical trials on the effectiveness of such inhibitors against endemic and emerging coronaviruses (203). A promising animal study revealed the protective effect of passive immunotherapy with immune serum from MERS-immune camels on mice infected with MERS-CoV (204). Passive immunotherapy using convalescent plasma is another strategy that can be used for treating COVID-19-infected, critically ill patients (205)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T129","span":{"begin":551,"end":556},"obj":"Body_part"}],"attributes":[{"id":"A129","pred":"uberon_id","subj":"T129","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Further assessment is necessary before confirming the effectiveness of such combination therapy. In addition, to prevent further community and nosocomial spread of COVID-19, the postprocedure risk management program should not be neglected (309). Development of broad-spectrum inhibitors against the human coronaviral pathogens will help to facilitate clinical trials on the effectiveness of such inhibitors against endemic and emerging coronaviruses (203). A promising animal study revealed the protective effect of passive immunotherapy with immune serum from MERS-immune camels on mice infected with MERS-CoV (204). Passive immunotherapy using convalescent plasma is another strategy that can be used for treating COVID-19-infected, critically ill patients (205)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1028","span":{"begin":164,"end":172},"obj":"Disease"},{"id":"T1029","span":{"begin":717,"end":725},"obj":"Disease"}],"attributes":[{"id":"A1028","pred":"mondo_id","subj":"T1028","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A1029","pred":"mondo_id","subj":"T1029","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Further assessment is necessary before confirming the effectiveness of such combination therapy. In addition, to prevent further community and nosocomial spread of COVID-19, the postprocedure risk management program should not be neglected (309). Development of broad-spectrum inhibitors against the human coronaviral pathogens will help to facilitate clinical trials on the effectiveness of such inhibitors against endemic and emerging coronaviruses (203). A promising animal study revealed the protective effect of passive immunotherapy with immune serum from MERS-immune camels on mice infected with MERS-CoV (204). Passive immunotherapy using convalescent plasma is another strategy that can be used for treating COVID-19-infected, critically ill patients (205)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T111","span":{"begin":300,"end":305},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T112","span":{"begin":452,"end":455},"obj":"http://purl.obolibrary.org/obo/CLO_0001180"},{"id":"T113","span":{"begin":458,"end":459},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T114","span":{"begin":470,"end":476},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_33208"},{"id":"T115","span":{"begin":574,"end":580},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9837"},{"id":"T116","span":{"begin":660,"end":666},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"Further assessment is necessary before confirming the effectiveness of such combination therapy. In addition, to prevent further community and nosocomial spread of COVID-19, the postprocedure risk management program should not be neglected (309). Development of broad-spectrum inhibitors against the human coronaviral pathogens will help to facilitate clinical trials on the effectiveness of such inhibitors against endemic and emerging coronaviruses (203). A promising animal study revealed the protective effect of passive immunotherapy with immune serum from MERS-immune camels on mice infected with MERS-CoV (204). Passive immunotherapy using convalescent plasma is another strategy that can be used for treating COVID-19-infected, critically ill patients (205)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T232","span":{"begin":277,"end":287},"obj":"Chemical"},{"id":"T233","span":{"begin":397,"end":407},"obj":"Chemical"}],"attributes":[{"id":"A232","pred":"chebi_id","subj":"T232","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A233","pred":"chebi_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Further assessment is necessary before confirming the effectiveness of such combination therapy. In addition, to prevent further community and nosocomial spread of COVID-19, the postprocedure risk management program should not be neglected (309). Development of broad-spectrum inhibitors against the human coronaviral pathogens will help to facilitate clinical trials on the effectiveness of such inhibitors against endemic and emerging coronaviruses (203). A promising animal study revealed the protective effect of passive immunotherapy with immune serum from MERS-immune camels on mice infected with MERS-CoV (204). Passive immunotherapy using convalescent plasma is another strategy that can be used for treating COVID-19-infected, critically ill patients (205)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T783","span":{"begin":0,"end":96},"obj":"Sentence"},{"id":"T784","span":{"begin":97,"end":246},"obj":"Sentence"},{"id":"T785","span":{"begin":247,"end":457},"obj":"Sentence"},{"id":"T786","span":{"begin":458,"end":618},"obj":"Sentence"},{"id":"T787","span":{"begin":619,"end":766},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Further assessment is necessary before confirming the effectiveness of such combination therapy. In addition, to prevent further community and nosocomial spread of COVID-19, the postprocedure risk management program should not be neglected (309). Development of broad-spectrum inhibitors against the human coronaviral pathogens will help to facilitate clinical trials on the effectiveness of such inhibitors against endemic and emerging coronaviruses (203). A promising animal study revealed the protective effect of passive immunotherapy with immune serum from MERS-immune camels on mice infected with MERS-CoV (204). Passive immunotherapy using convalescent plasma is another strategy that can be used for treating COVID-19-infected, critically ill patients (205)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3151","span":{"begin":300,"end":305},"obj":"Species"},{"id":"3152","span":{"begin":306,"end":317},"obj":"Species"},{"id":"3153","span":{"begin":437,"end":450},"obj":"Species"},{"id":"3154","span":{"begin":574,"end":580},"obj":"Species"},{"id":"3155","span":{"begin":584,"end":588},"obj":"Species"},{"id":"3156","span":{"begin":603,"end":611},"obj":"Species"},{"id":"3157","span":{"begin":751,"end":759},"obj":"Species"},{"id":"3158","span":{"begin":164,"end":172},"obj":"Disease"},{"id":"3159","span":{"begin":589,"end":597},"obj":"Disease"},{"id":"3160","span":{"begin":717,"end":734},"obj":"Disease"},{"id":"3161","span":{"begin":736,"end":750},"obj":"Disease"}],"attributes":[{"id":"A3151","pred":"tao:has_database_id","subj":"3151","obj":"Tax:9606"},{"id":"A3152","pred":"tao:has_database_id","subj":"3152","obj":"Tax:11118"},{"id":"A3153","pred":"tao:has_database_id","subj":"3153","obj":"Tax:11118"},{"id":"A3154","pred":"tao:has_database_id","subj":"3154","obj":"Tax:9838"},{"id":"A3155","pred":"tao:has_database_id","subj":"3155","obj":"Tax:10090"},{"id":"A3156","pred":"tao:has_database_id","subj":"3156","obj":"Tax:1335626"},{"id":"A3157","pred":"tao:has_database_id","subj":"3157","obj":"Tax:9606"},{"id":"A3158","pred":"tao:has_database_id","subj":"3158","obj":"MESH:C000657245"},{"id":"A3159","pred":"tao:has_database_id","subj":"3159","obj":"MESH:D007239"},{"id":"A3160","pred":"tao:has_database_id","subj":"3160","obj":"MESH:C000657245"},{"id":"A3161","pred":"tao:has_database_id","subj":"3161","obj":"MESH:D016638"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Further assessment is necessary before confirming the effectiveness of such combination therapy. In addition, to prevent further community and nosocomial spread of COVID-19, the postprocedure risk management program should not be neglected (309). Development of broad-spectrum inhibitors against the human coronaviral pathogens will help to facilitate clinical trials on the effectiveness of such inhibitors against endemic and emerging coronaviruses (203). A promising animal study revealed the protective effect of passive immunotherapy with immune serum from MERS-immune camels on mice infected with MERS-CoV (204). Passive immunotherapy using convalescent plasma is another strategy that can be used for treating COVID-19-infected, critically ill patients (205)."}